NEW YORK (GenomeWeb) – San Diego-based Diagnomics will begin offering comprehensive and customized pharmacogenetic test reports through a strategic partnership with Translational Software.
The PGx analysis will be performed on Illumina's Global Screening Array and a comprehensive report on how the detected markers are likely to impact the patient's drug response, metabolism, and treatment efficacy will be generated using Translational Software's platform.
According to Diagnomics, the comprehensive report will include actionable information, such as guidance on dosing, as well as information contained in drug labeling, in practice guidelines, and from research studies. Patients will receive a card with their report that contains their PGx results that they can carry with them.
Diagnomics said in a statement that it intends to collaborate with Translational Software to advance specific reports for pain, cancer, and cardiovascular drugs. "These customized reports, in addition to the comprehensive version, will provide valuable insights on how patients respond to opioids, anticoagulants, statins, chemotherapies, … and promote patients' curated treatment plans," Diagnomics said.